Several
quinones have been found to be effective in the treatment of some forms of
cancer; however, their cumulative heart toxicity limits their use. The
cannabinoid quinone HU-331 [3S,4R-
p-benzoquinone-3-hydroxy-2-p-mentha-(1,8)-dien-3-yl-5-pentyl] is highly effective against
tumor xenografts in nude mice. We report now a comparison of the anticancer activity of
HU-331 and its
cardiotoxicity with those of
doxorubicin in vivo. General toxicity was assayed in Sabra, nude and SCID-NOD mice. The anticancer activity in vivo was assessed by measurement of the
tumors with an external caliper in HT-29 and Raji
tumor-bearing mice and by weighing the excised
tumors. Left ventricular function was evaluated with transthoracic echocardiography. Myelotoxicity was evaluated by blood cell count. Cardiac
troponin T (cTnT) plasma levels were determined by immunoassay.
HU-331 was found to be much less cardiotoxic than
doxorubicin. The control and the HU-331-treated groups gained weight, whereas the
doxorubicin-treated group lost weight during the study. In HT-29 colon
carcinoma, the
tumor weight in the HU-331-treated group was 54% smaller than in the control group and 30% smaller than in the
doxorubicin-treated group. In Raji
lymphoma, the
tumor weight in the HU-331-treated group was 65% smaller than in the control group and 33% smaller than in the
doxorubicin-treated group. In contrast to
doxorubicin,
HU-331 did not generate
reactive oxygen species in mice hearts (measured by protein carbonylation levels and
malondialdehyde levels). In vivo,
HU-331 was more active and less toxic than
doxorubicin and thus it has a high potential for development as a new anticancer
drug.